Heart health and lung cancer treatment: what new research is showing
Better lung cancer treatment means more attention to cardiac health
Treatment for lung cancer has improved significantly in recent years.
For people with stage III non small cell lung cancer, combining chemoradiotherapy followed by immunotherapy is now standard care. This approach has helped improve outcomes and survival.
But as treatment improves, attention is turning to something else: the longer term effects of treatment, including heart health.
A new review published in The Lancet Oncology looks at what we know so far about the cardiac effects of combining these treatments.
Why heart health is part of the conversation
Both radiotherapy and immunotherapy can affect the heart.
Radiotherapy to the chest can expose parts of the heart to radiation
Some immunotherapy treatments have been linked to inflammation affecting the heart
When these treatments are used together, the combined effect is not yet fully understood.
The review brings together existing studies and highlights a key point:
we may be seeing a new pattern of cardiac risk in lung cancer care.
What the research found
The authors looked at available clinical and preclinical evidence and identified several important questions:
Does immunotherapy add to the cardiac risk from chemoradiotherapy?
Does previous radiotherapy change how the heart responds to immunotherapy?
How should cardiac side effects be measured and monitored?
Are there ways to reduce or manage these risks?
The evidence so far is mixed, and in many cases limited. This means there is still uncertainty about the scale and timing of cardiac effects.
Gaps that still need to be addressed
The review also highlights areas where more research is needed:
Understanding long term effects in people living beyond treatment
Defining clear and consistent ways to measure cardiac outcomes
Looking beyond non small cell lung cancer to other thoracic cancers
Exploring how newer radiotherapy techniques may reduce risk
What this means in practice
This is not about raising alarm.
It is about recognising that as outcomes improve, the focus of care also needs to evolve.
More people are living longer after lung cancer treatment. That means:
follow up care needs to include cardiac monitoring where appropriate
clinicians need clearer guidance on risk and management
research needs to keep pace with how treatment is changing
A shift in how we think about care
This research reflects a broader shift in cancer care.
It is no longer only about treating the cancer. It is also about how people live during and after treatment.
Heart health is becoming part of that conversation.
Source
Kim Y et al. Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review. The Lancet Oncology, 2026.